 LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 PRNewswire - Liminal BioSciences Inc. Nasdaq: LMNL Liminal BioSciences or the Company, announced today that, its subsidiary Prometic Biotherapeutics Inc. PBT has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher PRV for USD105M. The PRV was granted by the U.S. Food and Drug Administration FDA with the approval of Ryplazim plasminogen, human-tvmh Ryplazim, for treatment of patients with plasminogen deficiency type 1 hypoplasminogenia. 